Anti-interleukin-1 treatment among patients with familial Mediterranean fever resistant to colchicine treatment.
Retrospective analysis
Palavras-chave:
Familial Mediterranean fever, Quality of life, Interleukin-1 receptor antagonist protein, ColchicineResumo
BACKGROUND: Up to 5% of familial Mediterranean fever (FMF) cases are unresponsive to colchicine, through resistance, side effects and toxicity. Anakinra is an alternative treatment for FMF patients whose disease remains uncontrolled with colchicine. We aimed to evaluate anti-interleukin-1 treatment regard-ing clinical findings, laboratory parameters and quality of life (QoL) among FMF patients presenting resis-tance and toxicity towards colchicine. DESIGN AND SETTING: Descriptive observational study at the rheumatology clinic, Adnan Menderes University Medical School, Aydın, Turkey. METHODS: Among the patients included, age, sex, MEFV genotypes, acute-phase reactants, hepatic/renal function tests, average colchicine dose, disease duration, attack frequency, attack duration, disease se-verity, proteinuria, amyloidosis and QoL were evaluated. Colchicine resistance was defined as > 6 typical episodes/year or > 3 per 4-6 months. Kolmogorov-Smirnov, Friedman and two-way analysis of variance tests were used for statistical analyses. RESULTS: Between 2015 and 2017, 14 FMF patients receiving anakinra were enrolled. The mean colchicine dose was 1.7 ± 0.3 mg/day before use of anakinra. Ten patients were attack-free after treatment, while three showed reductions of at least 50% in attack frequency, attack duration and disease severity. Protein-uria levels in all patients with renal amyloidosis decreased after treatment. QoL among patients with renal amyloidosis differed significantly from QoL among non-amyloidosis patients. Mean visual analogue scale scores significantly improved in both groups after use of anakinra. CONCLUSIONS: Use of anakinra reduced attack frequency and proteinuria and acute-phase reactant lev-els, and improved QoL, with only a few uncomplicated side effects among colchicine-resistant or intol-erant FMF patients. Injection-site reactions of severity insufficient to require discontinuation of treatment were seen.
Downloads
Referências
Sarı İ, Birlik M, Kasifoğlu T. Familial Mediterranean fever: An updated review. Eur J Rheumatol. 2014;1(1):21-33. PMID: 27708867; doi: 10.5152/ eurjrheum.2014.006.
Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351(9103):659-64. PMID: 9500348; doi: 10.1016/S0140-6736(97)09408-7.
Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43(3):387-91. PMID: 23742958; doi: 10.1016/j.semarthrit.2013.04.011.
Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644-51. PMID: 26802180; doi: 10.1136/ annrheumdis-2015-208690.
Ozen S, Kone-Paut I, Gül A. Colchicine resistance and intolerance in familial Mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47(10:115-20. PMID: 28413100; doi: 10.1016/j.semarthrit.2017.03.006.
Tufan A, Babaoglu MO, Akdogan A, et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol. 2007;34(7):1540-4. PMID: 17610314.
Sargin G, Senturk T, Cildag S. Effective treatment with azathioprine for renal amyloidosis secondary to familial Mediterranean fever. Scand J Rheumatol. 2016;45(4):337-8. PMID: 26982335; doi: 10.3109/03009742.2016.1139175.
Seyahi E, Ozdogan H, Masatlioglu S, Yazici H. Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient. Clin Exp Rheumatol. 2002;20(4 Suppl 26):S43-4. PMID: 12371635.
Tunca M, Akar S, Soytürk M, et al. The effect of interferon alpha administration on acute attacks of familial Mediterranean fever: A double-blind, placebo-controlled trial. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S37-40. PMID: 15515782.
Onat AM, Oztürk MA, Ozçakar L, et al. Selective serotonin reuptake inhibitors reduce the attack frequency in familial Mediterranean fever. Tohoku J Exp Med. 2007;211(1):9-14. PMID: 17204829; doi: 10.1620/ tjem.211.9.
Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004;10(3):134-7. PMID: 17043487; doi: 10.1097/01.rhu.0000128856.13595.eb.
van der Hilst JCh, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S. Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature. Biologics. 2016;10:75-80. PMID: 27110096; doi: 10.2147/BTT.S102954.
Sevillano ÁM, Hernandez E, Gonzalez E, et al. Anakinra induces complete remission of nephrotic syndrome in a patient with familial Mediterranean fever and amyloidosis. Nefrologia. 2016;36(1):63-6. PMID: 26409501; doi: 10.1016/j.nefro.2015.06.026.
Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik
T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med. 2007;146(110:825-6. PMID: 17548423.
Kucuksahin O, Yildizgoren MT, Ilgen U, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial Mediterranean fever. Mod Rheumatol. 2017;27(2):350-5. PMID: 27328763; doi: 10.1080/14397595.2016.1194510.
Cetin P, Sari I, Sozeri B, et al. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation. 2015;38(1):27-31. PMID: 25139580; doi: 10.1007/s10753-014-0004-1.
Akar S, Cetin P, Kalyoncu U, et al. A Nationwide Experience with the Off-label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. Arthritis Care Res (Hoboken). 2018;70(7):1090-4. PMID: 28992387; doi: 10.1002/acr.23446.
Bartov JB, Ali Y. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout, chronic kidney disease, and aplastic anemia. J Clin Rheumatol. 2013;19(8):454-6. PMID: 24263151; doi: 10.1097/ RHU.0000000000000047.
Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10):1879-85. PMID: 9336425; doi: 10.1002/art.1780401023.
Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265-71. PMID: 21277619; doi: 10.1016/j.semarthrit.2010.11.003.
Venhoff N, Voll RE, Glaser C, et al. IL-1-blockade with Anakinra during pregnancy: Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever. Z Rheumatol. 2018 Mar;77(2):127-134. PMID: 28752409; doi: 10.1007/s00393-017-0354-9.
Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1-11. PMID: 15643295.
Varan Ö, Kucuk H, Babaoglu H, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2018:1-4. PMID: 29578360; doi: 10.1080/14397595.2018.1457469.
Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302. PMID: 4636899; doi: 10.1056/NEJM197212212872514.
Zemer D, Pras M, Sohar E, et al. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314(16):1001-5. PMID: 3515182; doi: 10.1056/ NEJM198604173141601.
Lidar M, Yonath H, Shechter N, et al. Incomplete response to colchicine in M694V homozygote FMF patients. Autoimmun Rev. 2012;12(1):72-6. PMID: 22884555; doi: 10.1016/j.autrev.2012.07.025.
Corsia A, Georgin-Lavialle S, Hentgen V, et al. A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet J Rare Dis. 2017;12(1):54. PMID: 28302131; doi: 10.1186/ s13023-017-0609-1.
Ben-Zvi I, Kukuy O, Giat E, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2017;69(4):854-62. PMID: 27860460; doi: 10.1002/art.39995.
Buskila D, Zaks N, Neumann L, et al. Quality of life of patients with familial Mediterranean fever. Clin Exp Rheumatol. 1997;15(4):355-60. PMID: 9272294.
Deger SM, Ozturk MA, Demirag MD, et al. Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients. Rheumatol Int. 2011;31(5):623-8. PMID: 20049448; doi: 10.1007/s00296-009-1334-4.
Sahin S, Yalcin I, Senel S, et al. Assessment of life quality of familial Mediterranean fever patients by short form-36 and its relationship with disease parameters. Eur Rev Med Pharmacol Sci. 2013;17(7):958-63. PMID: 23640444.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
